Lima, Peru.
A Peruvian participant at eclinical trial of the vaccine against covid-19 from the Chinese laboratory Sinopharm fbecame ill with pneumonia caused by coronavirus, an event that does not mean at all that the vaccine is ineffectiveHe warned those responsible for the investigation on Tuesday.
Cayetano Heredia University of Peru (UPCH), responsible for the study in which victim, confirmed this Tuesday the death of the woman without disclosing whether he actually received it vaccine or in his case he had been given a placebo, how to do it essay time.
6,000 volunteers participated in the UPCH to participate in the clinical trial of vaccine of Sinopharm, to whom 2,000 were inoculated vaccine made with the variant of virus SARS-CoV-2 from Wuhan, to another 2,000 that of Beijing and another 2,000 had one placebo.
After receiving the placebo, the woman developed infectious picture from covid-19 regularly and was complicated by suffer from diabetes and hypertension, two risk factors associated with much of deaths for this disease in Peru, as indicated by Germán Málaga, the lead investigator of the clinical trial.
If you received any of vaccines atinvolved in the study, infection and the woman’s backside may be due effectiveness of these, it is not 100%, UPCH recalled, which remains to be confirmed.
MORE THAN ONE SERIOUS WEEK
The university reported that the volunteer was diagnosed and treated from the beginning of the disease, then a early hospitalization and later when his condition passed to the worst, had access to a mechanical ventilator in an intensive care unit (UCI).
The study and research center mentioned that “it received everything indicated care to try this disease and their complications and he fought for his life for more than a week, unable to win its onslaught “.
The fatal result was communicated to the safety committee and the competent authorities for finalization investigate to clarify this episode.
UPCH also mentioned that all the volunteers studied are informed that they must continue with usual prevention to avoid infection covid-19, because the participants do not know if they have received the vaccine or placebo.
The UPCH-led Sinopharm vaccine trial was suspended by the National Institutes of Health (INS) for almost a week in December after a 64-year-old volunteer developed a series of neurological symptoms, including weakness in the legs, similar to the syndrome of Guillain Barre.
WAIT FOR THE FIRST VACCINE
The Peruvian government is waiting to receive the first 38 million doses from vaccine of Sinopharm which it has committed to purchase this year 2021.
Despite the fact that the Executive announced that the first batch of vaccines it would be in January, it seems that it will not be after the public administration has failed to complete the transport and a group of private companies have committed to pay and process the plane what will bring vaccinations
Sinopharm is a priori the contract Peru higher to get vaccines after also agreeing to buy 14 million doses at the British laboratory AstraZeneca and they guaranteed 13.3 million doses provided by the multilateral initiative COVAX, which all added should be enough for iimmunize its entire population.
See: Biden is looking to vaccinate all Americans by the end of August
However, a recent survey showed that a 48% of Peruvians you do not want to receive the vaccine because you think it will not be safe, mainly because it has developed so quickly and normal clinical studies.
Peru is currently in the middle of the second wave of covid-19 infections, with its health system collapsing again and the number of deaths accelerating every day.
In total it records more than one million dand cases symptomatic confirmed, of which nearly 40,000 died, but reports from regional governments that matter asymptomatic and suspicious, they collectively bring the number of cases to over two million. EFE